Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

As Aducanumab’s US FDA Review Progressed, Support Grew For Accelerated Approval

Jun 23 2021

• By Sue Sutter

Momentum — The idea of accelerated approval gained momentum late in Aduhelm's regulatory review. • Source: Alamy

Related Content

Biogen’s Aducanumab: Why Accelerated Approval Might, And Might Not, Be An Option For US FDA

Nov 13 2020

Biogen’s Aducanumab Falls Hard At Panel Review, Leaving US FDA In A Tight Spot

Nov 08 2020

Aduhelm’s ‘Complex’ Circumstances Drove Extensive In-House Advice Process Before Accelerated Approval, Cavazzoni Says

Jun 23 2021

Woodcock Attributes Aduhelm Approval Controversy To ‘Process Problems’

Jun 23 2021

Aducanumab Accelerated Approval Reflects US FDA Flexibility But Raises Doubts About Confirmatory Trial

Jun 08 2021

Related Companies

Biogen, Inc.

Additional Topics

United States Approvals Drug Review Review Pathway Regulation BioPharmaceutical Neurology

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window